MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection

Bibliography

• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15
   PubMed Web of Science ®Google Scholar
• Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology 2013;57:2117-23
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009;46:222-9
   PubMed Web of Science ®Google Scholar
• Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013;56:206-12
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007;40:110-15
   PubMed Web of Science ®Google Scholar
• Gentile I, De Stefano A, Di Flumeri G, et al. Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. In Vivo 2013;27:527-9
   PubMed Web of Science ®Google Scholar
• Bourlière M, Poordad F, Vrijens B, et al. High medication adherence in HCV-infected patients taking a triple-DAA regimen for 12 weeks. Hepatology 2013;58:740A
   Web of Science ®Google Scholar
• Mele A, Spada E, Sagliocca L, et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J Hepatol 2001;35:284-9
   PubMed Web of Science ®Google Scholar
• Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013;65:83-4
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:15S-20S
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepat Mon 2013;13:e8352
   PubMed Web of Science ®Google Scholar
• Zampino R CN, Cirillo G, Boemio A, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hep 2013;20:517-23
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Pisaturo M, Stanzione M, et al. Presentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;13:00466-7
   Google Scholar
• Coppola N, Zampino R, Bellini G, et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013;21:00687-3
   Google Scholar
• Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-700
   PubMed Web of Science ®Google Scholar
• Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28:141-52
   PubMed Web of Science ®Google Scholar
• Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013;27:773-7
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009;43:81-7
   PubMed Web of Science ®Google Scholar
• Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014;13:20-6
   Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013;164:e305-12
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012;44:49-54
   PubMedGoogle Scholar
• Fusco F, D'Anzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother 2013;14:2533-44
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 2013;1:318-27
   Google Scholar
• Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52:778
   PubMed Web of Science ®Google Scholar
• Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53
   PubMed Web of Science ®Google Scholar
• Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004;74:406-13
   PubMed Web of Science ®Google Scholar
• Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87
   PubMed Web of Science ®Google Scholar
• Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-91
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Tonziello G, et al. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis 2012;12:1471-2334
   Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011;54:887-93
   PubMed Web of Science ®Google Scholar
• Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20:35-40
   PubMedGoogle Scholar
• Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver Int 2009;29:248-52
   PubMed Web of Science ®Google Scholar
• Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75
   PubMedGoogle Scholar
• Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009;24:190-6
   PubMed Web of Science ®Google Scholar
• Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17:5184-90
   PubMed Web of Science ®Google Scholar
• Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18:800-5
   PubMed Web of Science ®Google Scholar
• Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
   PubMed Web of Science ®Google Scholar
• Coppola N, Pascalis SD, Pisaturo M, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013;58:748-50
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733-42
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Zappulo E, et al. Efficacy and Safety of Sofosbuvir in Treatment of Chronic Hepatitis C: the Dawn of the a New Era. Rev Recent Clin Trials 2014; In press
   Google Scholar
• Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56:S88-S100
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014; In press
   Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV Infection. Expert Opin Investig Drugs 2014;23:561-71
   PubMed Web of Science ®Google Scholar
• FDA approves new treatment for hepatitis C virus. Release FN. 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm [Last accessed 19 February 2014]
   Google Scholar
• Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. FDA. FDA press release. 2013. Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377920.htm [Last accessed 17 January 2014]
   Google Scholar
• European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C. Agency EM. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500155469.pdf [Last accessed 1 February 2014]
   Google Scholar
• Harper S, McCauley JA, Rudd MT, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. Acs Med Chem Lett 2012;3:332-6
   PubMed Web of Science ®Google Scholar
• Kuethe J, Zhong YL, Yasuda N, et al. Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172. Org Lett 2013;15:4174-7
   PubMed Web of Science ®Google Scholar
• Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus: world. J Gastroenterol 2007;13(43):5673-81
   Web of Science ®Google Scholar
• Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56:4161-7
   PubMed Web of Science ®Google Scholar
• Shah U, Jayne C, Chackalamannil S, et al. Novel quinoline-based P2–P4 macrocyclic derivatives as pan-genotypic HCV NS3/4a protease inhibitors. ACS Med Chem Lett 2014;5:264-9
   PubMed Web of Science ®Google Scholar
• Brainard DM, Petry A, Anderson MS, et al. safety, tolerability, and pharmacokinetics ater single and multiple doses oF MK-5172, A novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in healthy subjects. Hepatology 2010;52:1216A-7A
   PubMed Web of Science ®Google Scholar
• Caro L, Anderson M, Du L, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship for MK-5172, a novel hepatitis C virus (HCV) NS3/4A protease inhibitor, in genotype 1 and genotype 3 HCV-infected patients. Hepatology 2011;54:1005A-A
   Web of Science ®Google Scholar
• Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers. Hepatology 2013;58:437
   Web of Science ®Google Scholar
• Yeh WW, Caro L, Huang X, et al. No pharmacokinetic interaction between HCV protease inhibitor MK-5172 and HCV NS5A inhibitor MK-8742 in healthy volunteers. Hepatology 2013;58:438
   Google Scholar
• Yeh WW, IP F, Bifano M, et al. Lack of pharmacokinetic interaction between HCV protease inhibitor MK-5172 and HCV NS5A inhibitor daclatasvir in healthy volunteers. Hepatology 2013;58:430-1
   Google Scholar
• Talaty JE, Caro L, Yeh WW, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and efavirenz in normal healthy volunteers. Hepatology 2013;58:445
   Web of Science ®Google Scholar
• Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers. Hepatology 2013;58:442-3
   PubMed Web of Science ®Google Scholar
• Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and IV and oral rifampin in healthy volunteers. Hepatology 2013;58:446-7
   Web of Science ®Google Scholar
• Ludmerer S, Carroll S, McCauley J, et al. MK-5172, a novel macrocyclic inhibitor of NS3/4a protease demonstrates efficacy against viral resistance in the chimpanzee model of chronic hepatitis C virus infection. Antiviral Res 2010;86:A21-1
   Web of Science ®Google Scholar
• Petry AS, Fraser IP, O'Mara E, et al. Safety and antiviral activity of MK-5172, a next generation HCV N53/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 2011;54:531A-A
   Web of Science ®Google Scholar
• Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138:913-21
   PubMed Web of Science ®Google Scholar
• Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54:1114-22
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8
   PubMed Web of Science ®Google Scholar
• Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 2009;10:181-9
   PubMed Web of Science ®Google Scholar
• Pasquinelli C, McPhee F, Eley T, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 2012;56:1838-44
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002
   PubMed Web of Science ®Google Scholar
• Manns M, Vierling JM, Bacon BR, et al. High sustained viral response at 12-and 24-week follow-up of MK-5172 with pegylated interferon ALFA-2b and ribavirin (PR) in HCV genotype 1 treatment-naive non-cirrhotic patients. J Hepatol 2013;58:S30-0
   Web of Science ®Google Scholar
• Howe A, Ludmerer S, Liu R, et al. MK-5172 in combination with PEG-interferon/ribavirin demonstrates robust efficacy and a low rate of resistance-associated virologic failure in treatment naive genotype 1 chronic HCV-infected patients. J Hepatol 2013;58:S487-S87
   Web of Science ®Google Scholar
• Vierling JM, Lagging M, Brown AS, et al. High efficacy at lower doses of MK-5172 25 mg and 50 mg daily for 12 weeks in HCV genotype (G) 1 treatment-naive non-cirrhotic patients. Hepatology 2013;58:757-8
   Web of Science ®Google Scholar
• Lawitz E, Vierling JM, Murillo A, et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: the C-worthy study. Hepatology 2013;58:244-5
   Google Scholar
• Gane EJ, Ben Ari Z, Mollison L, et al. Efficacy and safety of an interferon-free regimen of MK-5172 + ribavirin for 12 weeks or 24 weeks in treatment naive, non-cirrhotic subjects with HCV GT1 infection: the C-SPIRIT study. Hepatology 2013;58:748-9
   Google Scholar
• Caro L, Du L, Huang S, et al. Relationship between transaminase levels and plasma pharmacokinetics following administration of MK-5172 with pegylated interferon ALFA-2B and ribavirin (PR) to HCV genotype (G) 1 treatment-naive patients. J Hepatol 2013;58:S328-S28
   Web of Science ®Google Scholar
• Graham D, Acosta A, Guo Z, et al. MK-5172, A second generation HCV NS3/4A protease inhibitor is active against common resistance associated variants (RAVS) and exhibits cross-genotype activity. Hepatology 2011;54:543A-A
   Web of Science ®Google Scholar
• Lahser F, Liu R, Bystol K, et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons. Hepatology 2012;56:236A-A
   Web of Science ®Google Scholar
• Strizki JM, Barnard RJO, Cheney C, et al. Evaluation of ns3 amino acid variants in a phase 1b study of genotype 1 (GT1) and gt3 infected patients with the HCV protease inhibitor, MK-5172. J Hepatol 2012;56:S479-S79
   Web of Science ®Google Scholar
• Barnard RJ, Howe AY, Strizki JM, et al. No MK-5172 Resistance Associated Variants (RAVs) identified in a vanguard cohort of treatment-naive, genotype 1, non-cirrhotic patients enrolled in the MK-5172 phase 2B study. Hepatology 2012;56:719A-A
   Web of Science ®Google Scholar
• Borgia G, Carleo MA, Gaeta GB, et al. Hepatitis B in pregnancy. World J Gastroenterol 2012;18:4677-83
   PubMed Web of Science ®Google Scholar
• Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012;56:1247-53
   PubMed Web of Science ®Google Scholar
• Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013;33:80-4
   PubMed Web of Science ®Google Scholar